Specific molecular markers in hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 3, 2007, Pages 241-247

  Yao, Deng Fu ^a   Dong, Zhi Zhen ^a   Yao, Min ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Carcinoma; Early diagnosis; Hepatocellular; Metastasis of tumor; Molecular marker; Postoperative recurrence

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; KI 67 ANTIGEN; MESSENGER RNA; MOLECULAR MARKER; SOMATOMEDIN B; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA1;

CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GENE MUTATION; GENETIC MARKER; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; MEDICAL LITERATURE; MEDLINE; METASTASIS POTENTIAL; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; GAMMA-GLUTAMYLTRANSFERASE; HEAT-SHOCK PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; RNA, MESSENGER; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 34250319273     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 2004;5: 118-125.
2. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001;411:390-395.
3. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003;3:8-24.
4. Tang ZY. Hepatocellular carcinoma - cause, treatment and metastasis. World J Gastroenterol 2001;7:445-454.
5. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
6. Kanematsu T, Furui J, Yanaga K, Okudaira S, Shimada M, Shirabe K. A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery 2002;131(1 Suppl):S153-158.
7. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2004;11:383-393.
8. Jiang YF, Yang ZH, Hu JQ. Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 2000;6:61-65.
9. Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 2004;28:376-381.
10. Yao DF, Jiang DR, Huang ZW, Lu JX, Tao QY, Yu ZJ, et al. Abnormal expressiom of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000;88:761-769.
11. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003;23:1747-1753.
12. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1):57-63.
13. Wu W, Yao DF, Gu LH, Fan JW, Lu XF, Li XH, et al. Determination of hepatoma-specific alpha-fetoprotein by a mini-column affinity chromatography method. Chin J Clin Lab Sci 2006;24:10-12.
14. Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001;16:105-111.
15. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003;197:753-758.
16. Kamoto T, Satomura S, Yoshiki T, Okada Y, Henmi F, Nishiyama H, et al. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 2002;32:472-476.
17. Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002; 20:305-309.
18. Bae JS, Park SJ, Park KB, Paik SY, Ryu JK, Choi CK, et al. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med 2005;20: 80-85.
19. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
20. Cillo U, Navaglia F, Vitale A, Molari A, Basso D, Bassanello M, et al. Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. Clin Chim Acta 2004;347:129-138.
21. Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, et al. Association between recurrence of hepatocellular carcinoma and alpha-fetoprotein messenger RNA levels in peripheral blood. Surg Today 2005;35:1033-1041.
22. Yao DF, Dong ZZ, Yang DM, Zhu YS, Jiang DR, Lu JX. Peripheral blood AFP-mRNA amplification in the diagnosis and differential diagnosis of hepatocellular carcinoma. Chin J Gen Surg 2000;15:474-477.
23. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002;35:853-860.
24. Plebani M, D'Amico DF. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:6920-6925.
25. Yao DF, Dong ZZ, Yao DB, Wu XH, Wu W, Qiu LW, et al. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. Hepatobiliary Pancreat Dis Int 2004;3:564-570.
26. Tang QY, Yao DF, Lu JX, Wu XH, Meng XY. Expression and alterations of different molecular form gamma-glutamyl transferase and total RNA concentration during the carcinogenesis of rat hepatoma. World J Gastroenterol 1999;5:356-358.
27. Yao DF, Huang ZW, Chen SZ, Huang JF, Lu JX, Xiao MB, et al. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum gamma-glutamyltransferase. Am J Clin Pathol 1998;110:743-749.
28. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002;118:211-215.
29. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358.
30. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001;186:153-168.
31. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003;35:685-693.
32. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001;34:859-867.
33. Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 2004;24:21-28.
34. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133-143.
35. Kim YJ, Lee HS, Im JP, Min BH, Kim HD, Jeong JB, et al. Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 2003;35:196-202.
36. Yao DF, Zou L, Yao M, Yao DB. Abnormal expression of transforming growth factor-β1 in hepatocellular carcinoma and pathological characteristics of its relationship with HBV replication. J Gastroenterol Hepatol 2006;21(S2):A170.
37. Dong ZZ, Zou L, Qiu LW, Yao DF. Expressions of hepatoma and circulating TGF-b1-mRNA and its clinical values in diagnosis of patients with liver cancer. J Gastroenterol Hepatol 2006;21(S2):A172.
38. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001;54:138-144.
39. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, Wands JR. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006;44:446-457.
40. Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol 2003;9:267-270.
41. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, et al. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:4655-4660.
42. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology 2004;40:276-283.
43. Lee CM, Hsu CY, Eng HL, Huang WS, Lu SN, Changchien CS, et al. Telomerase activity and telomerase catalytic subunit in hepatocellular carcinoma. Hepatogastroenterology 2004;51:796-800.
44. Mu J, Wei LX. Telomere and telomerase in oncology. Cell Res 2002;12:1-7.
45. Onishi T, Nouso K, Higashi T, Toshikuni N, Nakatsukasa H, Kobayashi Y, et al. Cellular distribution of telomerase reverse transcriptase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:1168-1174.
46. Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, et al. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int 2005;4:544-549.
47. Meng SD, Song J, Rao Z, Tien P, Gao GF. Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. J Immunol Methods 2002;264:29-35.
48. Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother 2005;54: 971-980.
49. Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol 2005;174:195-204.
50. Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005;7:104-108.
51. Yao DF, Wu XH, Su XQ, Yao M, Wu W, Qiu LW, et al. Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2006;5:381-386.
52. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J Korean Med Sci 2005;20:829-834.
53. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130:497-513.
54. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005;229:157-169.